Principal Financial Group Inc. Sells 95,974 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Principal Financial Group Inc. lowered its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 26.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 267,037 shares of the biotechnology company's stock after selling 95,974 shares during the quarter. Principal Financial Group Inc. owned about 0.28% of Sarepta Therapeutics worth $33,350,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of SRPT. Garden State Investment Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth $2,115,000. Tidal Investments LLC grew its position in shares of Sarepta Therapeutics by 91.2% in the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock valued at $704,000 after purchasing an additional 2,688 shares during the last quarter. World Investment Advisors LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $2,418,000. Sunbelt Securities Inc. lifted its position in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded up $1.24 on Tuesday, hitting $121.90. 204,864 shares of the company were exchanged, compared to its average volume of 1,213,239. Sarepta Therapeutics, Inc. has a 1-year low of $91.34 and a 1-year high of $173.25. The firm has a 50 day moving average of $123.22 and a two-hundred day moving average of $131.51. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $11.64 billion, a P/E ratio of 97.52 and a beta of 0.77.

Analysts Set New Price Targets

A number of brokerages have recently commented on SRPT. HC Wainwright reiterated a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, December 19th. Raymond James reissued an "outperform" rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating on the stock in a report on Wednesday, November 27th. StockNews.com cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Finally, William Blair raised Sarepta Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and an average target price of $178.71.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares of the company's stock, valued at $738,234. This trade represents a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.